Mumbai , March 30 ( IANS ) US-based global healthcare company Johnson &amp;amp ; Johnson on Monday announced the selection of a lead COVID-19 vaccine candidate , adding that it expects to initiate testing of the vaccine in humans at the latest by September this year .
The first batches of a COVID-19 vaccine could be available for emergency use authorisation in early 2021 , the company said .
Through a landmark new partnership , Biomedical Advanced Research and Development Authority ( BARDA ) , which is part of the Office of the Assistant Secretary for Preparedness and Response ( ASPR ) at the U .
Department of Health and Human Services , and Johnson &amp;amp ; Johnson together have committed more than $1 billion of investment to co-fund vaccine research , development , and clinical testing .
Johnson &amp;amp ; Johnson said it will use its validated vaccine platform and is allocating resources , including personnel and infrastructure globally , as needed , to focus on these efforts .
Separately , BARDA and Johnson &amp;amp ; Johnson have provided additional funding that will enable expansion of their ongoing work to identify potential antiviral treatments @ @ @ @ @ @ @ @ @ @ commitment , Johnson &amp;amp ; Johnson is also expanding the company 's global manufacturing capacity , including through the establishment of new U .
vaccine manufacturing capabilities and scaling up capacity in other countries .
The additional capacity will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally , the company said .
" The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible , " Alex Gorsky , Chairman and Chief Executive Officer , Johnson &amp;amp ; Johnson , said in a statement .
" Johnson &amp;amp ; Johnson is well positioned through our combination of scientific expertise , operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic , " Gorsky added .
Johnson &amp;amp ; Johnson began efforts in January 2020 , as soon as the novel coronavirus ( COVID-19 ) sequence became available , to research @ @ @ @ @ @ @ @ @ @ of Johnson &amp;amp ; Johnson , in collaboration with Beth Israel Deaconess Medical Center , part of Harvard Medical School , constructed and tested multiple vaccine candidates using the Janssen AdVac technology .
Through collaborations with scientists at multiple academic institutions , the vaccine constructs were then tested to identify those with the most promise in producing an immune response in preclinical testing .
Based on this work , Johnson &amp;amp ; Johnson has identified a lead COVID-19 vaccine candidate ( with two back-ups ) , which will progress into the first manufacturing steps .
Under an accelerated timeline , the company is aiming to initiate a Phase 1 clinical study in September 2020 , with clinical data on safety and efficacy expected to be available by the end of the year .
This could allow vaccine availability for emergency use in early 2021 .
For comparison , the typical vaccine development process involves a number of different research stages , spanning 5 to 7 years , before a candidate is even considered for approval .
